ArticleJournal of robotic surgery2026
Development and internal validation of a biparametric MRI-based nomogram for predicting extraprostatic extension in patients undergoing robot-assisted radical prostatectomy.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify predictors of extraprostatic extension (EPE) in prostate cancer and develop a nomogram to guide nerve-sparing decision-making in robot-assisted radical prostatectomy (RARP). The study included 402 patients who underwent RARP between January 2020 and December 2025. Fifty five patients were excluded as they received neoadjuvant therapy and did not undergo magnetic resonance imaging (MRI) based on the Prostate Imaging Reporting and Data System (PI-RADS). For side-specific analysis, data were analyzed on a lobe-by-lobe basis; among a total of 694 lobes, 73 were excluded due to being difficult to evaluate for EPE or lacking PI-RADS evaluation. Clinical, imaging, and biopsy factors associated with EPE per side were retrospectively analyzed, and a nomogram was developed to predict EPE. Among the 621 lobes analyzed, 101 (16.3%) were EPE-positive, while 520 (83.7%) were EPE-negative. Multivariate analysis identified prostate-specific antigen (PSA) (odds ratio [OR]: 1.041, 95% confidence interval [CI]: 1.003-1.081, p = 0.034), PIRADS category (OR: 2.630, 95%CI: 1.049-6.593, p = 0.039), suspected EPE on MRI (OR: 2.887, 95%CI: 1.461-5.702, p = 0.002), biopsy Grade group (OR: 2.502, 95%CI: 1.239-5.052, p = 0.011), and biopsy positivity in the peripheral zone (OR: 4.080, 95%CI: 1.744-9.548, p = 0.001) as significant factors associated with EPE. Subsequently, a nomogram was created based on these factors. The area under the curve of the nomogram was 0.868, indicating high diagnostic accuracy. In summary, we developed an accurate nomogram for predicting EPE. This nomogram may contribute to the appropriate selection of nerve-sparing grades for RARP.
Indexed as
Identifiers
42486920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.